Fungus on items, stagnant water: Maharashtra FDA suspends food licence of Zepto's Dharavi outlet
The Maharashtra Food and Drug Administration (FDA) has suspended the food business licence of the Dharavi outlet of Kiranakart Technologies Pvt Ltd, the parent company of Zepto, following an inspection on Saturday which revealed multiple violations of food safety norms at the distribution centre.
The inspection was carried out by food safety officer Ram Bodke, based on directions from Minister of State for FDA Yogesh Kadam, and under the supervision of Mangesh Mane, Joint Commissioner, Food. The probe unearthed a slew of violations at the distribution centre under the Food Safety and Standards Act, 2006, and the accompanying licensing regulations, the FDA claimed.
Among the most serious findings included the alleged visible fungal growth on food items, stagnant and clogged water near storage areas which indicated poor sanitation, improper cold storage with temperatures not maintained as per norms, and wet, unclean floors and food products stored haphazardly, including directly on the ground, according to the regulatory authority.
The FDA also claimed that expired food products were kept alongside fresh stock, without clear separation.
In response, Anupamaa Balasaheb Patil, Assistant Commissioner, Food, issued an immediate suspension order under section 32(3) of the Food Safety Act and Regulation 2.1.8(4) of the Licensing and Registration Rules. The order mandates that the facility cannot resume operations until it demonstrates full compliance and receives formal clearance from the licensing authority.
An official statement from Zepto on the matter is awaited.
The FDA said that the action is part of its ongoing crackdown on unsafe food practices. 'Public health cannot be compromised. We are committed to strict and transparent enforcement,' said Rajesh Narvekar, Commissioner, FDA.
The licence will remain suspended until the Dharavi facility clears a follow-up inspection and receives formal reinstatement approval from the FDA.
The FDA is the state's principal regulatory authority dedicated to ensuring the safety, quality, and compliance of food products, medicines, and cosmetics. Operating under the Department of Medical Education and Pharmaceuticals, it is responsible for implementing and enforcing various legislations pertaining to food safety and drugs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Amid staff crunch, FDA to appoint 40 food safety officers this week
Mumbai: After operating with just five food safety officers (FSOs) for nearly a year, the city's Food and Drug Administration (FDA) is expected to appoint at least 40 new FSOs by June 7, in a bid to address a severe staffing shortfall. The drug department under the FDA is similarly stretched thin with only five field officers in the city. It may take another year to reach its required strength of 25 to 30 here. Officials say the shortage significantly hampered inspections and enforcement, overburdening the limited staff. Following action taken against a Zepto facility in Dharavi on Sunday, FDA officials admitted they currently lack the manpower to inspect similar warehouses operated by delivery platforms. "Food safety officers are the field workers who conduct sampling and routine inspections. Without adequate numbers, essential tasks like testing for milk adulteration or checking ice quality can't happen at the large scale required," said Mangesh Mane, joint commissioner (Food). Although over 40 officers are expected to be appointed within days, Mane said training will take another month or two. "We expect them to join the workforce by October," he added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Switch to UnionBank Rewards Card UnionBank Credit Card Apply Now Undo FDA commissioner Rajesh Narvekar said the food division has 350 sanctioned posts, but only 132 are filled, leaving a gap of 218 officers. After repeated proposals to the govt and the Maharashtra Public Service Commission, 194 food safety officers and 8 assistant commissioners were finally selected, bringing the department's total strength to just over 300. However, according to food safety norms, one officer per 1,000 food business operators, the FDA needs at least 1,100 officers. The drug department, meanwhile, has 200 sanctioned posts but only 48 filled, with 152 vacancies still open. A revised recruitment proposal has been submitted to MPSC, but officials say it will take another year. The persistent shortfall is largely due to a prolonged pause in recruitment drives and a wave of retirements, promotions, and transfers over the past year or more. "We are meeting our targets by working extra hours. Leaves are being sacrificed, but we're trying not to let it affect our functioning," said an official from the drug department. Still, gaps remain. "There's no major problem due to shortfall in issuing manufacturing licenses after conducting their inspections," said Narvekar. "The problem is in monitoring retailers and wholesalers," he added. Abhay Pandey, president of the All Food and Drug Licence Holders Foundation, warned of serious public health consequences. "Random sampling at retail stores and distributor levels simply isn't happening for more than a year at a scale it should. Without it, there's no way to ensure quality control," he said.
Time of India
5 hours ago
- Time of India
Entrepreneur finds alternative to make areca plates safer after US ban
Mangaluru: Entrepreneur and researcher Nivedan Nempe has developed an innovative, eco-friendly alternative following the recent US ban on arecanut leaf sheath dinnerware. His intervention comes at a crucial time, as areca growers and industry experts from Karnataka's areca belt have appealed to Prime Minister Narendra Modi to seek the lifting of the restriction. The US Food and Drug Administration (FDA) issued an import alert banning dinnerware made from areca catechu sheaths, citing the presence of naturally occurring toxins that may migrate into food at unsafe levels. The FDA's concerns significantly impacted India's $400-500 million areca plate industry, with nearly 80–85% of exports directed to the US. Most manufacturers are concentrated in Dakshina Kannada and Shivamogga, and the ban threatens the livelihoods of many families. Nivedan, founder of Areca Tea and operating in Udupi and Shivamogga, acknowledged the FDA's concerns and told TOI: "As a preventive step, the FDA banned imports. But this severely affects Indian manufacturers. The Indian industry made efforts, including writing to the FDA, but the industry is at risk." In response, Nempe engineered a food-grade, anti-microbial paper lining that acts as a barrier between the food and the areca plate, preventing toxin migration and fungal growth. "The material is certified, heat-resistant up to 300°C, durable, printable, and gives a premium finish. It meets international safety standards without altering the existing production process," he said. While the innovation may increase production costs by 10–15%, Nivedan believes that it is the best way forward. "Our lab results were positive on all parameters. It even looks better than bagasse plates. My goal is to safeguard the industry and support the farmers by supplying this new food-grade paper."
&w=3840&q=100)
First Post
11 hours ago
- First Post
US okays Moderna's 'next generation' Covid-19 vaccine
The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spikevax (mRNA-1273) by refining its immune target read more Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS Moderna, a vaccine manufacturer, said late last week that the FDA has authorised its next-generation COVID-19 vaccine. The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spikevax (mRNA-1273) by refining its immune target. Moderna's approval was based on a phase 3 randomised controlled trial involving 11,400 participants ages 12 and older. The trial found that a 10-microgram (μg) dose of mNexspike demonstrated a 9.3% higher relative vaccine efficacy (rVE) compared to a 50-μg dose of Spikevax, with a 13.5% higher rVE in adults ages 65 and older. The two vaccinations have identical safety profiles, according to the manufacturer. STORY CONTINUES BELOW THIS AD The approval 'adds an important new tool to help protect people at high risk of severe disease from COVID-19,' Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the US has handled COVID-19 vaccines until now, reflecting scepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The news came just days after the Trump administration cancelled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results. STORY CONTINUES BELOW THIS AD
